Comment from American Society of Hematology

Summary: The American Society of Hematology (ASH) supports the draft guidance on New Approach Methodologies (NAMs) but recommends clarifying that NAMs can support both toxicity and efficacy assessments. They also urge the FDA to provide specific examples and case studies to reduce uncertainty for sponsors regarding how NAM data should be integrated with traditional nonclinical data.